Smoking and IPMN malignant progression - 18/04/17
Abstract |
Background |
Patients with intraductal papillary mucinous neoplasm (IPMN) are at risk for invasive pancreatic cancer. We aim to characterize the impact of smoking on IPMN malignant progression.
Methods |
Patients undergoing pancreatic resection for IPMN (1991–2015) were retrospectively reviewed using a prospectively collected database.
Results |
Of 422 patients identified, 324 had complete data for analysis; 55% were smokers. Smoking status did not impact IPMN malignant progression (smokers/non-smokers: 22%/18% invasive grade; p = 0.5).
Smokers were younger than non-smokers at the time of IPMN diagnosis (63 versus 68 years; p = 0.001). This association also held in the invasive IPMN subgroup (65 versus 72 years, p = 0.01). Despite this observation, rate of symptoms at diagnosis, cancer stage, and median survival were the same between smokers and non-smokers.
Conclusion |
Although smoking is not associated with IPMN malignant progression, invasive IPMN is diagnosed at a younger age in smokers. These data suggest tobacco exposure may accelerate IPMN malignant progression.
Le texte complet de cet article est disponible en PDF.Keywords : Intraductal papillary mucinous neoplasm (IPMN), Smoking, Age
Plan
Vol 213 - N° 3
P. 494-497 - mars 2017 Retour au numéro
Article précédent
- Tranexamic acid and the gut barrier: Protection by inhibition of trypsin uptake and activation of downstream intestinal proteases
- Mark E. Diebel, Lawrence N. Diebel, David M. Liberati
- Assessing surgical residents' imaging interpretation skills
- Joseph J. Eid, Francisco Igor B. Macedo, Edsa Negussie, Vijay K. Mittal
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?